Biosimilar Development News

  1. Innovent Releases The ORIENT-31 Phase 3 Study First Interim Analysis Results Of Sintilimab Plus BYVASDA (Bevacizumab Biosimilar Injection) And Chemotherapy In Patients With EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer Who Progressed After EGFR-TKI 11/21/2021

    Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced first interim analysis results of the randomized, double-blinded, multi-center Phase 3 ORIENT-31 study conducted in China evaluating sintilimab and anti-VEGF antibody combination therapy (i.e., sintilimab plus BYVASDA® [bevacizumab biosimilar injection] combined with chemotherapy [pemetrexed and cisplatin]) in patients with EGFR-mutated non-squamous non-small cell lung-cancer (nsqNSCLC) who progressed after EGFR-TKI therapy in an oral presentation at the ESMO (European Society for Medical Oncology) Virtual Plenary: November 2021 (Abstract #300)

  2. Biosimilars Market Size To Surpass US$ 66.2B By 2030 11/19/2021

    The global biosimilars market size was reached at US$ 13.2 billion in 2020. The rising prevalence of diseases and the effective treatment of these chronic diseases at affordable costs are the two major drivers of the global biosimilars market.

  3. Walgreens Prescription Savings Club Offers Steep Savings On Viatris’ Long-Acting Insulin 11/18/2021

    Walgreens today announced that Viatris’ long-acting interchangeable Insulin Glargine (insulin glargine-yfgn) injection, co-developed with Biocon Biologics, will be offered through the Walgreens Prescription Savings Club, saving members up to 80 percent off the cash price of comparable long-acting insulins purchased at Walgreens

  4. New White Paper Highlights Barriers And Opportunities To Drive Biosimilar Adoption In The United States 11/17/2021

    Biologic medicines are among the most innovative drugs to treat many life-threatening conditions, including cancer and autoimmune diseases.

  5. Viatris and Biocon Biologics Announce Launch Of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection And Insulin Glargine (insulin glargine-yfgn) Injection 11/16/2021

    Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. today announced the U.S. launch of interchangeable biosimilars SEMGLEE® (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

  6. Biologics & Biosimilars Summit Convenes Physicians, Advocates And Policymakers To Discuss Access 11/11/2021

    On Wednesday, November 17, the Biologics Prescribers Collaborative, a project of the Alliance for Patient Access, will virtually convene the sixth annual National Policy & Advocacy Summit on Biologics.

  7. Prime Therapeutics Backs First Interchangeable Insulin Biosimilar Semglee® 11/3/2021

    Prime Therapeutics LLC (Prime), a leading pharmacy benefit manager (PBM) serving nearly 33 million members, will be preferring Viatris' biosimilar Semglee® (insulin glargine-yfgn, the branded product) injection and Insulin Glargine (insulin glargine-yfgn, the unbranded product) injection, co-developed with Biocon Biologics, on its national formularies as part of the pharmacy benefit.

  8. Biosimilars Canada Encourages Stakeholders To Join #GlobalBiosimilarsWeek 11/1/2021

    Biosimilars Canada, in collaboration with the International Generic and Biosimilar Medicines Association (IGBA), invites biosimilars stakeholders to take part in the second annual Global Biosimilars Week from November 1 to 5.

  9. А Phase III Study Proves The Efficacy Of The Bevacizumab Biosimilar BCD-021 In Patients With Late Stages Of Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 10/27/2021

    New results for Phase III study of BCD-021, a bevacizumab biosimilar, were presented as a poster at the European Society for Medical Oncology (ESMO) Congress 2021.

  10. Biosimilars Forum To Congress: Incentivize Biosimilars In Build Back Better Act 10/26/2021

    The Biosimilars Forum sent a letter to House and Senate leadership urging Congress to incentivize biosimilars in the Build Better Back Act to help lower prescription drug costs for Americans.